Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Recruiting now · Phase 1/Phase 2

Conditions studied: Advanced Solid Tumors

In brief

The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab or ipilimumab and nivolumab.

Key facts

Study ID

NCT05533697

Run by

ModernaTX, Inc.

People needed

361

Starts

2022-09-01

Expected to finish

2032-02-18

Last updated by the study team

2026-07-14

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University Hospital Southampton NHS Foundation Trust — Southampton, United Kingdom (enrolling)
• UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California, United States (enrolling)
• University of Colorado Cancer Center — Aurora, Colorado, United States (enrolling)
• George Washington University — Washington D.C., District of Columbia, United States (enrolling)
• Orlando Health UF Health Cancer Center — Orlando, Florida, United States (enrolling)
• The University of Chicago Medicine — Chicago, Illinois, United States (enrolling)
• Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
• Dana Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
• Henry Ford Hospital — Detroit, Michigan, United States (enrolling)
• Washington University — St Louis, Missouri, United States (enrolling)
• John Theurer Cancer Center — Hackensack, New Jersey, United States (enrolling)
• NYU Langone Health-Perlmutter Cancer Center — New York, New York, United States (enrolling)
• Memorial Sloan Kettering Cancer Center - Melanoma & Immunotherapeutics — New York, New York, United States (enrolling)
• Imperial College London — London, United Kingdom (enrolling)
• The Christie NHS Foundation Trust - Cancer Research Centre — Manchester, United Kingdom (enrolling)
• Churchill Hospital — Oxford, United Kingdom (enrolling)
• The Angeles Clinic and Research Institute — Los Angeles, California, United States (enrolling)
• Sara Cannon Research Institute Tennessee — Nashville, Tennessee, United States (enrolling)
• Southside Cancer Center — Miranda, New South Wales, Australia (enrolling)
• Wollongong Hospital — Wollongong, New South Wales, Australia (enrolling)
• Melanoma Institute Australia — Wollstonecraft, New South Wales, Australia (enrolling)
• Austin Hospital — Melbourne, Victoria, Australia (enrolling)
• One Clinical Research — Nedlands, Western Australia, Australia (enrolling)
• Lungenfachklinik Immenhausen - Thoracic Oncology — Immenhausen, Hesse, Germany (enrolling)
• A.O. Santa Maria della Misericordia — Udine, Perugia, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.